Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.63Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 30.89%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant year-over-year growth in revenue, gross profit, and genomic segments, alongside improved adjusted EBITDA and strong guidance for future growth. The partnership with AstraZeneca and Pathos is seen as a major achievement. However, challenges remain with a negative adjusted EBITDA and the need to meter MRD volumes due to reimbursement issues.Company Guidance
During the Tempus First Quarter 2025 Financial Results Conference Call, Eric Lefkofsky, CEO, highlighted a strong start to the year with quarterly revenue growing 75.4% year-over-year to $255.7 million. Genomics revenue saw an 89% increase year-over-year, reaching $193.8 million. Oncology testing grew 31% year-over-year with a 20% increase in volume, while hereditary testing contributed $63.5 million with a 23% growth in units. Revenue from Data and Services totaled $61.9 million, marking a 43% year-over-year increase, with the Insights business growing 58%. Tempus generated $155.2 million in gross profit, reflecting a 99.8% year-over-year growth. The company reported an adjusted EBITDA loss of $16.2 million, an improvement from a $43.9 million loss in Q1 2024. Tempus raised its full-year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth. A significant highlight was a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos, bringing Tempus' total remaining contract value to over $1 billion, which Lefkofsky noted as a milestone toward advancing precision medicine.Record Revenue Growth
Quarterly revenue increased 75.4% year-over-year to $255.7 million.
Genomics Revenue Surge
Genomics revenue was $193.8 million, marking an 89% year-over-year growth.
Oncology and Hereditary Testing Growth
Oncology testing grew 31% year-over-year with approximately 20% volume growth. Hereditary testing revenue was $63.5 million, with units growing by 23%.
Significant Increase in Gross Profit
Quarterly gross profit increased 99.8% year-over-year to $155.2 million.
Improvement in Adjusted EBITDA
Adjusted EBITDA improved by $27.8 million year-over-year, from negative $43.9 million to negative $16.2 million.
Major Partnership with AstraZeneca and Pathos
Announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos.
Increased Full Year Revenue Guidance
Full year 2025 revenue guidance increased to $1.25 billion, representing about 80% year-over-year growth.
TEM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TEM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $52.19 | $58.76 | +12.59% |
Feb 24, 2025 | $69.57 | $59.10 | -15.05% |
Nov 04, 2024 | $49.50 | $44.50 | -10.10% |
Aug 06, 2024 | $40.65 | $38.82 | -4.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Tempus AI, Inc. Class A (TEM) report earnings?
Tempus AI, Inc. Class A (TEM) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Tempus AI, Inc. Class A (TEM) earnings time?
Tempus AI, Inc. Class A (TEM) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TEM EPS forecast?
TEM EPS forecast for the fiscal quarter 2025 (Q2) is -0.23.
